Department of Life Science and Biochemical Engineering, Sun Moon University, Asan 31460, Korea.
Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University, Asan 31460, Korea.
Int J Mol Sci. 2021 Oct 3;22(19):10731. doi: 10.3390/ijms221910731.
Hepatocellular carcinoma (HCC) is a malignant type of primary liver cancer with high incidence and mortality, worldwide. A major challenge in the treatment of HCC is chemotherapeutic resistance. It is therefore necessary to develop novel anticancer drugs for suppressing the growth of HCC cells and overcoming drug resistance for improving the treatment of HCC. Violacein is a deep violet-colored indole derivative that is produced by several bacterial strains, including , and it possesses numerous pharmacological properties, including antitumor activity. However, the therapeutic effects of violacein and the mechanism underlying its antitumor effect against HCC remain to be elucidated. This study is the first to demonstrate that violacein inhibits the proliferation and stemness of Huh7 and Hep3B HCC cells. The antiproliferative effect of violacein was attributed to cell cycle arrest at the sub-G1 phase and the induction of apoptotic cell death. Violacein induced nuclear condensation, dissipated mitochondrial membrane potential (MMP), increased generation of reactive oxygen species (ROS), activated the caspase cascade, and upregulated p53 and p21. The anticancer effect of violacein on HCC cells was also associated with the downregulation of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK)1/2 signaling. Violacein not only suppressed the proliferation and formation of tumorspheres of Huh7 and Hep3B cancer stem-like cells but also reduced the expression of key markers of cancer stemness, including CD133, Sox2, Oct4, and Nanog, by inhibiting the signal transducer and activator of transcription 3 (STAT3)/AKT/ERK pathways. These results suggest the therapeutic potential of violacein in effectively suppressing HCC by targeting the proliferation and stemness of HCC cells.
肝细胞癌 (HCC) 是一种恶性原发性肝癌,具有高发病率和死亡率,在全球范围内。HCC 治疗的主要挑战是化疗耐药性。因此,有必要开发新型抗癌药物来抑制 HCC 细胞的生长并克服耐药性,以改善 HCC 的治疗效果。紫色素是一种深紫色的吲哚衍生物,由包括 、在内的几种细菌菌株产生,具有多种药理特性,包括抗肿瘤活性。然而,紫色素的治疗效果及其对 HCC 的抗肿瘤作用机制仍有待阐明。这项研究首次表明,紫色素抑制 Huh7 和 Hep3B HCC 细胞的增殖和干性。紫色素的抗增殖作用归因于细胞周期在 sub-G1 期停滞和诱导细胞凋亡死亡。紫色素诱导核浓缩,耗散线粒体膜电位 (MMP),增加活性氧 (ROS) 的产生,激活半胱天冬酶级联反应,并上调 p53 和 p21。紫色素对 HCC 细胞的抗癌作用也与蛋白激酶 B (AKT) 和细胞外信号调节激酶 (ERK)1/2 信号通路的下调有关。紫色素不仅抑制了 Huh7 和 Hep3B 肿瘤干细胞样细胞的增殖和肿瘤球形成,而且通过抑制信号转导和转录激活因子 3 (STAT3)/AKT/ERK 通路降低了癌症干性的关键标志物的表达,包括 CD133、Sox2、Oct4 和 Nanog。这些结果表明,紫色素通过靶向 HCC 细胞的增殖和干性,具有有效抑制 HCC 的治疗潜力。